Amgen

Open: 219.34 Close: 218.76 Change: -0.58

How to know if Amgen Company Inc is a risky investment without reading the whole internet.

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, present, data, clinical, CodeBreaK, program, June, and the most common words in the summary are: amgen, state, district, court, new, oncology, inc, . One of the sentences in the summary was: Amgen Inc. Other searches related to this term that the AI found were: stockmarketlive, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day. Amgen share price has underperformed the S&P500 Index by -17.89% over the past year. The Amgen dividend yield is 3.63%.

Today's News

Amgen Inc. (AMGN) closed at $218.82 in the latest trading session, marking a -0.88% move from the prior day. Former Amgen employee loses attempt to reinstate takings claim. Amgen (NASDAQ:AMGN) will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. Amgens underlying earnings growth outpaced the notable return generated for shareholders over the past five years. New data from the CodeBreaK clinical trial program will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2-6 in Chicago. SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncologist Group, will also be presented June 6. Amgen share price has underperformed the S&P500 Index by -17.89% over the past year. The Amgen dividend yield is 3.63% based on the trailing twelve month period. Amgen is currently classified as a neutral market cap. Discover the metrics influencing Amgen s share price Unlock  with Google Or  unlock with your email Company about us Careers Product Guide. Amgen will present data from the CodeBreaK clinical trial program at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncologist Group, will be presented on June 6. Amgen v. Sanofi: Discussing the SCOTUS Decision Skip to Main Content Webinar June 6, 2023. Amgen is hosting a panel discussion on the critical role of engaging policymakers in building effective advocacy. #ASCO23 s theme, “Partnering with Patients,” is especially fitting. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Amgen scientists & researchers are in Washington, D.C. #PhRMAFlyIn23. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve peoples lives. Amgen announced the presentation of new clinical data for its #KRASG12C inhibitor in patients with advanced non-small cell lung cancer (NSCLC) & metastatic colorectal cancer (CRC) The company is exploring DLL3 as a potential immunotherapy target. Nearly 40% of Americans belong to a racial or ethnic minority, yet these groups continue to be underrepresented in clinical trials. Learn about the importance of biomarker testing in advanced lung cancer. Amgen will present data from the CodeBreaK clinical trial program at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. SCARLET, an Amgen funded investigator study sponsored by the West Japan Oncologist Group, will be presented on June 6. Amgen will present at the Goldman Sachs 44 th Annual Global Healthcare Conference at 2:20 p.m. on June 9, 2023. Amgen is committed to unlocking the potential of biology for patients. U.S. Supreme Court rules against Amgens bid to revive cholesterol drug patents. FTC faces uphill battle in its fight to block $27.8 billion takeover of Horizon Therapeutics. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. Amgen presents new lumakras® (sotorasib) codebreak 200 cns data at asco 2023. LUMAKRAS shows improved PFS vs Docetaxel across key Co-Alteration Subgroups in the Phase 3 CodeBreaK 200 Study LUMA KRAS G12 program. CodeBreaK clinical development program for sotorasib is designed to study patients with an advanced solid tumor with the KRAS  G12C mutation. Amgen has submitted MAAs in Argentina, Colombia, Kuwait, Malaysia, Mexico, Russia, Thailand and Turkey. Amgens LUMAKRAS/LUMYKRAS, a KRAS G12C inhibitor, is the leader in KRAS inhibition. The CodeBreaK clinical development program for sotorasib is designed to study patients with an advanced solid tumor with the KRAS  G12C mutation. Amgen inc. stock underperforms wed Wednesday when compared to competitors despite daily gains - marketwatch.com. Amgen Inc. stock -0.91% DJIA +0.13% SPX + 0.11% JNJ - 0.16% PFE -0.31% Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District AMGN LAWSUIT ALERT: Levi & Korsinsky notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, present, data, clinical, CodeBreaK, program, June, and the most common words in the summary are: amgen, state, district, court, new, oncology, inc, . One of the sentences in the summary was: Amgen Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #state #district #court #new #oncology #inc.